Vis enkel innførsel

dc.contributor.authorSekulic, Miroslav
dc.contributor.authorBatal, Ibrahim
dc.contributor.authorKudose, Satoru
dc.contributor.authorSantoriello, Dominick
dc.contributor.authorStokes, M. Barry
dc.contributor.authorJim, Belinda
dc.contributor.authorMarti, Hans Peter
dc.contributor.authorEikrem, Øystein Solberg
dc.contributor.authorRadhakrishnan, Jai
dc.contributor.authorD'Agati, Vivette D.
dc.contributor.authorMarkowitz, Glen S.
dc.date.accessioned2024-03-19T13:59:02Z
dc.date.available2024-03-19T13:59:02Z
dc.date.created2024-01-04T12:19:14Z
dc.date.issued2023
dc.identifier.issn2468-0249
dc.identifier.urihttps://hdl.handle.net/11250/3123176
dc.description.abstractIntroduction Hemophagocytic lymphohistiocytosis (HLH) is a clinicopathologic syndrome produced by dysregulated activation of the immune system. Acute kidney injury (AKI) and proteinuria have been infrequently described in the setting of HLH, and investigations of underlying histopathologic changes in the kidney are limited. Methods To characterize kidney pathology in HLH, a retrospective review of 30 patients’ clinical and laboratory data, and kidney tissue was performed (18 from autopsy, and 12 biopsied patients). Results HLH was associated with infection (83%), autoimmune disease (37%), and malignancy (20%), including 30% with concurrent autoimmune disease and infection. Nephrological presentations included subnephrotic range proteinuria (63%), AKI (63%), hematuria (33%), chronic kidney disease (CKD, 20%), nephrotic range proteinuria (13%), and nephrotic syndrome (7%); and 40% of patients required hemodialysis (HD). Among the 12 patients who underwent kidney biopsy, 6 subsequently showed improved kidney function and the remainder had progressive CKD with most progressing to end-stage kidney disease. Autopsy patients had a median terminal admission of 1 month, and 33% of the biopsied patients died (ranging from 0.3–5 months post-biopsy). Variable pathologies were identified, including acute tubular injury (ATI, 43%), lupus nephritis (LN, 23%), collapsing glomerulopathy (17%), thrombotic microangiopathy (TMA, 17%), and cortical necrosis (10%). Most autopsied patients had significant kidney pathology other than ATI that likely contributed to kidney function decline. A majority of patients with HLH exhibited kidney dysfunction that likely contributed to the poor prognosis. Conclusion Kidney dysfunction in HLH should not be assumed to be solely attributable to ATI, and in certain scenarios a kidney biopsy may be warranted.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleKidney Dysfunction and Pathology in the Setting of Hemophagocytic Lymphohistiocytosisen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.source.articlenumber410-422en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1016/j.ekir.2023.10.033
dc.identifier.cristin2220560
dc.source.journalKidney International Reportsen_US
dc.identifier.citationKidney International Reports. 2023, 9 (2), 410-422.en_US
dc.source.volume9en_US
dc.source.issue2en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal